Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | PDE4A | P27815 | 13/20 | 0.44 |
| ▸ | PDE7A | Q13946 | 4/20 | 0.44 |
| ▸ | JAK3 | P52333 | 2/20 | 0.37 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL193469 | 0.80 | GAA (0.63) | GAACYP1A2PDE4APDE7A | |
| SCHEMBL17141154 | 0.77 | JAK2 (0.57) | — | |
| SCHEMBL21231854 | 0.75 | GAA (0.57) | GAACYP1A2PDE4APDE7A | |
| SCHEMBL18961812 | 0.74 | GAA (1.00) | GAACYP1A2PDE4APDE7A | |
| SCHEMBL20340463 | 0.74 | SCN10A (0.40) | SCN10A | |
| SCHEMBL17141155 | 0.72 | JAK2 (0.38) | GAASCN10A | |
| SCHEMBL185651 | 0.71 | CYP1A2 (0.71) | GAACYP1A2PDE4APDE7A | |
| SCHEMBL1715548 | 0.70 | CYP1A2 (0.73) | GAACYP1A2PDE4APDE7A | |
| SCHEMBL23215086 | 0.69 | KMT2A (0.42) | PDE4A | |
| SCHEMBL193789 | 0.69 | CYP1A2 (0.57) | GAACYP1A2PDE4APDE7A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10011601-B2 | Substituted spirocyclic inhibitors of autotaxin | X-RX, INC. (US) | 2018-07-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10011601-B2 | Substituted spirocyclic inhibitors of autotaxin | ENPP2, SLC10A1, CXCR3 | GAA 1645/4885CYP1A2 2289/4885PDE4A 2816/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.